Last reviewed 2026-05-22 · How we verify

PBL 1427 capsules

Panacea Biotec Ltd · Phase 1 active Small molecule ✓ Verified May 2026

PBL 1427 capsules is a Small molecule drug developed by Panacea Biotec Ltd. It is currently in Phase 1 development.

PBL 1427 capsules are a small molecule intervention being studied for their safety, tolerability, and pharmacokinetics in a randomized, double-blind, placebo-controlled Phase I study. The study is focused on healthy volunteers and is also investigating the effects of PBL 1427 capsules on diabetes mellitus.

Likelihood of approval

9.6% vs 9.6% industry baseline

If approved by FDA: likely 2033–2036

Steps remaining: Phase 2 → Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 1 → approval rate +9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2033–2036	—
EMA	EU	2034–2037	+0.7 yr
MHRA	GB	2034–2037	+0.7 yr
Health Canada	CA	2034–2038	+0.9 yr
TGA	AU	2034–2038	+1.2 yr
PMDA	JP	2034–2038	+1.5 yr
NMPA	CN	2035–2039	+2.3 yr
MFDS	KR	2034–2038	+1.4 yr
CDSCO	IN	2034–2039	+1.8 yr
ANVISA	BR	2035–2039	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	PBL 1427 capsules
Sponsor	Panacea Biotec Ltd
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Study Of Single Ascending Doses Of PBL 1427 In Healthy Volunteers (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

PBL 1427 capsules CI brief — competitive landscape report
PBL 1427 capsules updates RSS · CI watch RSS
Panacea Biotec Ltd portfolio CI

Frequently asked questions about PBL 1427 capsules

What is PBL 1427 capsules?

PBL 1427 capsules is a Small molecule drug developed by Panacea Biotec Ltd.

Who makes PBL 1427 capsules?

PBL 1427 capsules is developed by Panacea Biotec Ltd (see full Panacea Biotec Ltd pipeline at /company/panacea-biotec-ltd).

What development phase is PBL 1427 capsules in?

PBL 1427 capsules is in Phase 1.

Manufacturer: Panacea Biotec Ltd — full pipeline

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing